MARKET

FDMT

FDMT

4D Molecular Therapeutics Inc.
NASDAQ
9.93
+0.05
+0.51%
Opening 10:20 03/26 EDT
OPEN
9.65
PREV CLOSE
9.88
HIGH
10.01
LOW
9.65
VOLUME
169.73K
TURNOVER
--
52 WEEK HIGH
12.34
52 WEEK LOW
2.235
MARKET CAP
506.94M
P/E (TTM)
-4.1057
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at FDMT last week (0316-0320)?
Weekly Report · 3d ago
Goldman Sachs Sticks to Their Buy Rating for 4D Molecular Therapeutics (FDMT)
TipRanks · 6d ago
4D Molecular Therapeutics Price Target Maintained With a $36.00/Share by HC Wainwright & Co.
Dow Jones · 6d ago
HC Wainwright & Co. Reiterates Buy on 4D Molecular Therapeutics, Maintains $36 Price Target
Benzinga · 6d ago
Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), Scholar Rock Holding (SRRK) and Acrivon Therapeutics, Inc. (ACRV)
TipRanks · 6d ago
Reimbursement and Pricing Pressures Threaten Commercial Outlook for 4D Molecular Therapeutics’ Gene Therapies
TipRanks · 6d ago
4D Molecular Therapeutics (FDMT) Q4 Profit Challenges Longstanding Loss Narrative
Simply Wall St · 6d ago
4D Molecular Therapeutics Price Target Raised to $35.00/Share From $32.00 by RBC Capital
Dow Jones · 03/19 14:13
More
About FDMT
4D Molecular Therapeutics, Inc. is a late-stage biotechnology company advancing durable and disease-targeted therapeutics. The Company's lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) with a single, safe, intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. Its lead indication for 4D-150 is wet age-related macular degeneration, which is in Phase III development, and second indication is diabetic macular edema. The Company is developing 4D-710 for the treatment of a range of people with cystic fibrosis independent of their specific CFTR mutation. 4D-710 is an investigational genetic medicine candidate using the A101 vector for the treatment of cystic fibrosis lung disease. The Company's non-core programs include 4D-175, 4D-725, and 4D-310.

Webull offers 4D Molecular Therapeutics Inc stock information, including NASDAQ: FDMT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FDMT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading FDMT stock methods without spending real money on the virtual paper trading platform.